About two weeks ago, I wondered whether the Street had caught up to Covidien (NYSE: COV )
. Apparently the answer is "no", as the company once again beat
expectations with strong sales growth and particularly strong
performance in its core surgical business.
I still don't think Covidien is particularly cheap, but that's a
complaint I make a lot these days in the health care sector. On a
relative basis, I think Covidien, Johnson & Johnson (NYSE: JNJ ) , and Stryker (NYSE: SYK ) are above-average calls on a relative basis, as they're exposed to improving procedural growth across multiple markets.
Follow this link for more:
Covidien plc. Delivers Yet Again
No comments:
Post a Comment